NIS1 Antibody

What is NIS1 and what are its recognized forms?

NIS1 refers to two distinct proteins in research contexts: the human sodium iodide symporter (hNIS) and the fungal necrosis-inducing secreted protein 1 (fungal NIS1). For human NIS, antibodies like VJ1 recognize an epitope located between amino acids 272 and 515 within the last three extracellular loops. This antibody detects only the native form of NIS and does not recognize the denatured form . The fungal NIS1 is a core effector conserved across Ascomycota and Basidiomycota that functions to suppress plant immune responses by targeting BAK1 and BIK1 kinases .

What experimental applications are appropriate for NIS1 antibodies?

For human NIS antibodies like VJ1, appropriate applications include:

• Flow cytometry for detecting NIS expression on cell surfaces

• Immunofluorescence studies on both intact and permeabilized cells

• Detection of lentiviral-transduced cells expressing NIS

• Visualization of NIS-expressing areas in virus-infected tumors

For research on fungal NIS1, antibodies are useful in:

• Co-immunoprecipitation assays to study interactions with plant immune kinases

• Detection of NIS1 secretion during fungal infection processes

• Tracking NIS1 localization during plant-pathogen interactions

What dilutions and staining protocols work best for NIS1 antibody applications?

Based on experimental data, the following protocols are recommended:

For optimal results, use fresh cells for flow cytometry and include appropriate controls to establish background staining levels .

How can researchers distinguish between cell surface and intracellular NIS expression?

Distinguishing between cell surface and intracellular NIS expression requires careful experimental design:

• For cell surface detection only: Use non-permeabilized cells with the VJ1 antibody, which recognizes an extracellular epitope. Maintain cells at 4°C during staining to prevent internalization.

• For total NIS expression: Permeabilize cells with 0.1% Triton X-100 or similar agent before antibody application to allow detection of both surface and intracellular NIS.

• For comparative analysis: Process parallel samples with and without permeabilization to quantify the ratio of surface to total NIS expression, which can provide insights into protein trafficking dynamics .

What are the optimal controls for NIS1 antibody experiments in different research contexts?

For human NIS antibody experiments:

• Positive control: Lentiviral transduced 293 cells or Mel624-hNIS-Neo cells stably expressing NIS

• Negative control: Parental non-transduced cell lines

• Isotype control: Mouse IgG at equivalent concentration to test for non-specific binding

• Blocking control: Pre-incubation with recombinant NIS protein to confirm specificity

For fungal NIS1 studies:

• Positive control: Plant tissues infected with wild-type fungi expressing NIS1

• Negative control: Plant tissues infected with NIS1-knockout fungi

• Specificity control: Co-expression of BAK1/BIK1 with and without NIS1 to verify interaction

How can researchers overcome challenges in detecting NIS1-mediated immune suppression?

Detecting NIS1-mediated immune suppression presents several methodological challenges. Researchers should:

• Use time-course experiments to distinguish between different cellular responses, as NIS1 from Colletotrichum orbiculare (CoNIS1) suppresses INF1-induced cell death at early timepoints (3 dpi) before eventually causing cell death at later timepoints (6 dpi) .

• Employ multiple readouts of immune responses, including:

  • Reactive oxygen species (ROS) burst measurements

  • Hypersensitive response (HR) cell death quantification

  • PAMP-triggered immunity markers

• Include appropriate timing controls, as different NIS1 homologs from various fungal species may exhibit distinct temporal dynamics in their suppression of immune responses .

What is the structural basis for NIS1 recognition and function?

The fungal NIS1 protein demonstrates a unique structural organization that is critical for its function:

• The crystal structure of Magnaporthe oryzae NIS1 (MoNIS1) reveals a β-barrel formed by eight β strands, representing a novel protein folding mode not previously reported .

• Hydrogen/deuterium exchange mass spectrometry (HDX-MS) analysis indicates that the β4-β5 loop and β5 strand of MoNIS1 are involved in interaction with BAK1 .

• Structural studies of human NIS show multiple transmembrane domains with extracellular loops, with the VJ1 antibody recognizing an epitope within the last three extracellular loops between amino acids 272-515 .

How do mutations in NIS1 affect its recognition by antibodies and its functional properties?

Mutational analyses have revealed critical insights:

• For fungal NIS1, the Y125A mutation abolishes the ability of CoNIS1∆C30 to suppress INF1-induced cell death without affecting protein stability, suggesting this residue is critical for functional interactions with immune components .

• Interestingly, CoNIS1∆C30 carrying the Y125A mutation still interacts with Arabidopsis BAK1 but may have reduced interaction with NbSERK3 and its paralogs, indicating species-specific interaction interfaces .

• Truncation analysis shows that CoNIS1∆C30, but not CoNIS1∆C60, maintains the ability to associate with both BAK1/SERK3 and BIK1, suggesting that the C-terminal region between residues 30-60 is critical for these interactions .

What are the mechanistic differences between various NIS1 homologs across fungal species?

NIS1 homologs from different fungal species exhibit notable functional differences:

• While Colletotrichum orbiculare NIS1 (CoNIS1) and Colletotrichum higginsianum NIS1 (ChNIS1) induce necrotic lesions in Nicotiana benthamiana, Magnaporthe oryzae NIS1 (MoNIS1) does not, indicating functional divergence .

• All three NIS1 homologs (CoNIS1, ChNIS1, and MoNIS1) suppress flg22-triggered ROS generation, but MoNIS1 shows weaker suppression of chitin-triggered ROS compared to CoNIS1 .

• Targeted gene disruption of NIS1 in M. oryzae severely reduces virulence on both barley and rice susceptible cultivars, highlighting the importance of this conserved effector for fungal pathogenicity despite functional variations .

How can researchers employ NIS1 antibodies in reporter gene assays and imaging studies?

NIS1 antibodies offer valuable tools for reporter gene assays and imaging:

• For human NIS as a reporter gene:

  • Flow cytometry with VJ1 antibody allows quantitative assessment of transduction efficiency in cells expressing hNIS

  • Immunofluorescence staining enables visualization of viral spread in tumor models expressing NIS as a reporter

  • Multi-color imaging can be achieved by combining Alexa 555-labeled secondary antibodies with nuclear stains like Hoechst 33342

• Experimental protocol for imaging virus-infected tumors:

  • Prepare OCT cryosections of tumor tissue infected with oncolytic viruses expressing NIS

  • Apply VJ1 primary antibody (1:50 dilution)

  • Detect with Alexa 555-conjugated secondary antibody

  • Counterstain with Hoechst 33342 for nuclear visualization

  • Image at 200x magnification to identify NIS-expressing regions

What approaches can resolve contradictory results when studying NIS1-BAK1 interactions?

When facing contradictory results in NIS1-BAK1 interaction studies, consider these methodological approaches:

• Employ multiple interaction detection methods:

  • Co-immunoprecipitation (co-IP) to confirm physical interaction

  • Bimolecular fluorescence complementation (BiFC) to visualize interactions in living cells

  • Surface plasmon resonance (SPR) to determine binding kinetics

  • Hydrogen/deuterium exchange mass spectrometry (HDX-MS) to identify interaction interfaces

• Test species-specific variations:

  • Different plant species express distinct BAK1 orthologs that may interact differently with NIS1

  • For example, CoNIS1 with Y125A mutation shows differential binding to Arabidopsis BAK1 versus Nicotiana benthamiana SERK3

• Consider the impact of experimental conditions:

  • In vitro versus in vivo conditions may yield different results

  • The presence of additional complex components can affect interaction dynamics

  • Post-translational modifications may significantly alter binding properties

How can chemical compounds be used to modulate NIS1-BAK1 interactions for research purposes?

Recent research has identified compounds that modulate NIS1-BAK1 interactions, offering new research tools:

• Screening approaches have identified compounds that block MoNIS1-OsBAK1 interaction in vitro and inhibit the virulence of M. oryzae on rice, demonstrating that disruption of this interaction could be a target for fungicide development .

• For research applications, these compounds can:

  • Serve as temporal inhibitors of NIS1 function in controlled experiments

  • Allow dose-dependent modulation of immune suppression

  • Provide chemical biology tools to study the kinetics of immune response recovery

  • Function as positive controls in screens for novel interaction inhibitors

• Experimental protocol for chemical inhibition studies:

  • Pre-incubate purified NIS1 protein with the candidate compound

  • Perform in vitro kinase assays with BAK1 to assess inhibition of interaction

  • Validate findings with co-IP experiments in the presence of the compound

  • Test compound effects on plant immune responses during fungal infection

How does NIS1 antibody performance differ across various experimental systems?

The performance of NIS1 antibodies varies across experimental systems:

• In human cell culture models:

  • VJ1 antibody shows strong surface staining in lentiviral transduced 293 cells expressing NIS

  • Effective labeling is observed in Mel624-hNIS-Neo cells with clear membrane localization

  • The antibody performs well in both adherent and suspension cell formats

• In plant-fungal pathosystems:

  • Antibodies against fungal NIS1 are valuable for tracking effector localization

  • Performance may vary depending on the plant species due to differences in tissue fixation requirements

  • Background issues may arise in green tissues due to autofluorescence

• In tumor models:

  • VJ1 antibody can detect areas of oncolytic virus infection expressing NIS in cryosectioned tumors

  • Optimization of fixation conditions is critical for maintaining epitope accessibility

  • Counterstaining with nuclear dyes provides important contextual information

What considerations are important when studying NIS1 in different host-pathogen systems?

When studying NIS1 across different host-pathogen systems, researchers should consider:

• Evolutionary conservation and divergence:

  • NIS1 is broadly conserved in filamentous fungi in both Ascomycota and Basidiomycota, suggesting it was present in their common ancestor

  • Functional differences exist between NIS1 homologs from different fungi, with varying abilities to induce necrosis or suppress specific immune responses

• Host target conservation:

  • BAK1 and BIK1 orthologs are present across plant species but may have evolved different interaction surfaces

  • The importance of these immune kinases for defense against Colletotrichum fungi has been confirmed in Arabidopsis

• Experimental design considerations:

  • Use multiple NIS1 homologs when possible to identify conserved versus species-specific activities

  • Include appropriate host species controls when studying cross-kingdom interactions

  • Consider timing differences in immune responses between host systems

How can researchers integrate NIS1 antibody studies with other molecular approaches?

Integrating NIS1 antibody studies with complementary molecular approaches enhances research depth:

• Combined antibody and genetic approaches:

  • Use NIS1 knockout fungi alongside antibody detection to correlate protein presence with function

  • Employ CRISPR-edited plant hosts with modified BAK1/BIK1 to study interaction specificity

  • Correlate antibody-detected localization with transcriptomics data to understand spatiotemporal dynamics

• Structure-function integration:

  • Utilize the crystal structure of MoNIS1 to guide antibody epitope mapping

  • Design mutant versions of NIS1 based on structural insights and test with antibodies for conformational changes

  • Combine HDX-MS interaction data with immunolocalization to understand in vivo relevance

• Protocol for integrative analysis:

  • Perform co-immunoprecipitation with NIS1 antibodies followed by mass spectrometry to identify novel interaction partners

  • Validate interactions with BiFC and FRET approaches

  • Correlate protein interactions with functional outcomes using immune response assays

What are common pitfalls in NIS1 antibody experiments and how can they be addressed?

Common pitfalls and their solutions include:

• False negatives in NIS1 detection:

  • Problem: VJ1 antibody recognizes only native NIS, not denatured forms

  • Solution: Avoid harsh fixation protocols; use gentle fixatives like 2% paraformaldehyde

  • Validation: Include positive control samples of known NIS-expressing cells

• Non-specific background in immunofluorescence:

  • Problem: High background can mask specific NIS1 signals

  • Solution: Optimize blocking conditions (5% BSA, 5% normal goat serum); include proper controls

  • Validation: Compare staining patterns with isotype control antibodies

• Interference in co-immunoprecipitation of NIS1 with BAK1/BIK1:

  • Problem: Weak or inconsistent pull-down results

  • Solution: Optimize detergent conditions; use chemical crosslinking to stabilize transient interactions

  • Validation: Perform reciprocal co-IPs (pulling down with anti-BAK1 and blotting for NIS1)

How should researchers validate antibody specificity for NIS1 research?

Comprehensive validation of NIS1 antibody specificity requires:

• Genetic validation approaches:

  • Test antibody reactivity against NIS1 knockout or knockdown samples

  • Perform detection in overexpression systems with tagged NIS1 variants

  • Compare reactivity patterns across closely related proteins to confirm specificity

• Biochemical validation:

  • Perform peptide competition assays with the epitope region

  • Evaluate reactivity against recombinant NIS1 protein

  • Test cross-reactivity with homologous proteins from related species

• Experimental controls to include:

  • Isotype control antibodies at matching concentrations

  • Secondary-only controls to assess non-specific binding

  • Dilution series to establish optimal signal-to-noise ratios

What quality control measures ensure reproducible NIS1 antibody results across experiments?

To ensure reproducibility in NIS1 antibody experiments:

• Standardized antibody handling:

  • Maintain consistent aliquoting and storage conditions (-20°C, avoid freeze-thaw cycles)

  • Record lot numbers and perform lot-to-lot validation

  • Establish internal reference standards for antibody performance

• Experimental normalization:

  • Include reference cell lines or tissues in each experiment

  • Use quantitative metrics such as mean fluorescence intensity ratios

  • Employ internal controls for immunoprecipitation efficiency

• Documentation and reporting standards:

  • Maintain detailed records of antibody source, lot, dilution, and incubation conditions

  • Document all image acquisition parameters (exposure, gain, offset)

  • Establish standard operating procedures for key applications and train all lab members accordingly

How might emerging technologies enhance NIS1 antibody applications?

Emerging technologies offer new opportunities for NIS1 antibody applications:

• Advanced imaging approaches:

  • Super-resolution microscopy can reveal nanoscale distribution of NIS1 and its targets

  • Live-cell imaging with antibody fragments can track dynamic interactions

  • Correlative light and electron microscopy can connect antibody localization with ultrastructural context

• Single-cell analysis:

  • Mass cytometry (CyTOF) with metal-conjugated NIS1 antibodies enables high-dimensional analysis

  • Single-cell sequencing combined with antibody-based cell sorting can correlate NIS1 expression with transcriptional states

  • Spatial transcriptomics with antibody detection can map NIS1 activity in tissue contexts

• Protein engineering approaches:

  • Development of single-domain antibodies against NIS1 for improved tissue penetration

  • Bispecific antibodies targeting NIS1 and its interaction partners simultaneously

  • Antibody-drug conjugates to specifically target NIS1-expressing cells

What unresolved questions remain about NIS1 structure and function?

Despite significant progress, several questions about NIS1 remain unanswered:

• Structural puzzles:

  • Complete structural characterization of human NIS, including transmembrane topology

  • Structural basis for the differential effects of NIS1 homologs from various fungal species

  • Conformational changes in NIS1 upon binding to target proteins

• Functional mysteries:

  • The evolutionary origin of NIS1 as a core effector and its acquisition via horizontal transfer in some species

  • Additional unidentified targets of NIS1 beyond BAK1 and BIK1

  • The role of NIS1 in non-pathogenic fungal species like the root endophyte Colletotrichum tofieldiae

• Research opportunities:

  • Comprehensive characterization of NIS1 post-translational modifications

  • Investigation of potential NIS1 interaction with other immune components

  • Development of NIS1-targeted strategies for crop protection

How can researchers contribute to the development of more specific NIS1 antibody tools?

Researchers can advance NIS1 antibody technology through:

• Epitope-focused antibody development:

  • Use the crystal structure of MoNIS1 to design antibodies targeting specific functional domains

  • Develop antibodies that distinguish between different NIS1 homologs based on key variable regions

  • Create conformation-specific antibodies that recognize active versus inactive NIS1 states

• Collaborative resource development:

  • Establish repositories of validated NIS1 antibodies with detailed performance characteristics

  • Create standardized reference materials for antibody validation

  • Develop open-source protocols optimized for different experimental systems

• Advanced antibody engineering:

  • Generate recombinant antibody fragments with improved tissue penetration for in vivo studies

  • Design antibody-based biosensors that report on NIS1-BAK1 interactions in real-time

  • Develop antibodies that selectively block specific NIS1 functions without affecting others